Chemistry:Actoxumab
From HandWiki
Short description: Chemical compound
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Clostridium difficile toxin A |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6476H10000N1740O2010S45 |
| Molar mass | 145836.11 g·mol−1 |
Actoxumab is a human monoclonal antibody designed for the prevention of recurrence of Clostridium difficile infection.[1]
This drug, along with bezlotoxumab, was developed through Phase II efficacy trials by a partnership between Medarex Inc and MassBiologics of the University of Massachusetts Medical School.[2] The project was then licensed to Merck & Co., Inc. for further development and commercialization.[3]
A study compared it with bezlotoxumab (that targets CD toxin-B) and found Actoxumab less effective.[4]
References
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council - Actoxumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/actoxumab.pdf.
- ↑ "Treatment with monoclonal antibodies against Clostridium difficile toxins". N. Engl. J. Med. 362 (3): 197–205. January 2010. doi:10.1056/NEJMoa0907635. PMID 20089970.
- ↑ "Merck & Co., Inc., Medarex, Inc. and Massachusetts Biologic Laboratories Sign Exclusive Licensing Agreement for Investigational Monoclonal Antibody Combination for Clostridium Difficile Infection". Press Release. Merck Sharp & Dohme Corp. http://www.merck.com/licensing/our-partnership/medarex-partnership.html.
- ↑ New treatment for C.diff infections reduces recurrences by 40%, study finds
 |  |
